J&J Levaquin Review Could Affect Bristol's Positioning Of Tequin
Executive Summary
The upcoming advisory committee review of a new indication for Ortho McNeil's Levaquin (levofloxacin) could affect Bristol-Myers Squibb's positioning of its pending quinolone antibiotic Tequin (gatifloxacin).You may also be interested in...
Sepracor Xopenex
Abbott will co-promote levalbuterol. Sepracor currently markets the single-isomer form of the asthma drug albuterol using its own 65-person sales force and a 155-person contract sales force provided by Innovex (1"The Pink Sheet" Oct. 11, p. 23). Including Abbott, there are now over 500 reps supporting Xopenex, Sepracor said
Sepracor Xopenex
Abbott will co-promote levalbuterol. Sepracor currently markets the single-isomer form of the asthma drug albuterol using its own 65-person sales force and a 155-person contract sales force provided by Innovex (1"The Pink Sheet" Oct. 11, p. 23). Including Abbott, there are now over 500 reps supporting Xopenex, Sepracor said
Ortho-McNeil Levaquin
The anti-infectives committee will review levofloxacin for the treatment of community acquired pneumonia due to penicillin-resistant S. pneumonia on the afternoon of Oct. 20. The committee will consider development of antimicrobial drugs for the treatment of catheter-related blood stream infections in the morning session, beginning at 9 a.m
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: